22446-37-3

Usage

Uses

Used in Pharmaceutical Industry:
(2-HYDROXY-PHENYL)-ACETIC ACID METHYL ESTER is used as a reactant in the preparation of caffeic acid phenylethyl esters for their antiproliferative properties. These esters have potential applications as therapeutic agents, particularly in the treatment of cancer, due to their ability to inhibit the proliferation of cancer cells and disrupt tumor growth.
Additionally, (2-HYDROXY-PHENYL)-ACETIC ACID METHYL ESTER may be utilized in other industries for various purposes, such as in the synthesis of other bioactive compounds or as an intermediate in the production of pharmaceuticals and nutraceuticals. Its versatility in chemical reactions and potential applications make it a valuable compound in the field of organic chemistry and drug development.

Synthesis Reference(s)

Synthetic Communications, 24, p. 2743, 1994 DOI: 10.1080/00397919408010590

InChI:InChI=1/C9H10O3/c1-12-9(11)6-7-4-2-3-5-8(7)10/h2-5,10H,6H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 614-75-5 2-Hydroxyphenylacetic acid 
• 101-41-7 benzeneacetic acid methyl ester 
• 75-36-5 acetyl chloride 
• 496-64-0 3-hydroxy-2-pyrone 
• 34805-49-7 methyl 3-nitrobut-3-enoate 
• 67-56-1 methanol 
• 2444-36-2 2'-chloro-benzeneacetic acid 
• 55359-65-4 1-methoxymethoxy-2-methylbenzene 
• 25458-50-8 α-(methoxymethoxy)phenyl acetic acid 
• 7440-44-0 pyrographite 
• 121985-99-7 2-hydroxy-2-(2-methoxyphenyl)acetonitrile 
• 93-25-4 2-methoxyphenylacetic acid 
• 845786-35-8 {2-[2-(tert-butyl-diphenyl-silanyl)-ethoxy]-phenyl}-acetic acid methyl ester 

Downstream Products

• 55842-25-6 α-Phenyl-(o-carbomethoxymethyl)-phenoxy-acetat 
• 103474-02-8 methyl 2-(2-phenoxyphenyl)acetate 
• 76251-01-9 methyl 2-(3,5-dibromo-2-hydroxyphenyl)acetate 
• 178118-34-8 [2-(4,6-dimethoxy-pyrimidin-2-yloxy)-phenyl]-acetic acid methyl ester 
• 374626-94-5 methyl 2-[2-(4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)ethoxy]phenylacetate 
• 374626-96-7 {2-[2-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374627-00-6 {2-[2-(4-isopropyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374626-98-9 {2-[2-(3-oxo-4-propyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374627-07-3 {2-[2-(4-isobutyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374627-04-0 {2-[2-(4-butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374627-09-5 {2-[2-(3-oxo-4-pentyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-ethoxy]-phenyl}-acetic acid methyl ester 
• 374108-25-5 (2-{2-[4-(2-acetoxy-ethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]-ethoxy}-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Regioselective Synthesis of Benzofuranones and Benzofurans

Reaction of 3-hydroxy-2-pyrones with nitroalkenes bearing ester groups gives benzofuranones. The reaction allows regioselective preparation of the benzofuranones with programmable substitution at any position. Complex substitution patterns are readily cre

Design and Synthesis of a Series of l-trans-4-Substituted Prolines as Selective Antagonists for the Ionotropic Glutamate Receptors Including Functional and X-ray Crystallographic Studies of New Subtype Selective Kainic Acid Receptor Subtype 1 (GluK1) Antagonist (2S,4R)-4-(2-Carboxyphenoxy)pyrrolidine-2-carboxylic Acid

Ionotropic glutamate receptor antagonists are valuable tool compounds for studies of neurological pathways in the central nervous system. On the basis of rational ligand design, a new class of selective antagonists, represented by (2S,4R)-4-(2-carboxyphenoxy)pyrrolidine-2-carboxylic acid (1b), for cloned homomeric kainic acid receptors subtype 1 (GluK1) was attained (Ki = 4 μM). In a functional assay, 1b displayed full antagonist activity with IC50 = 6 ± 2 μM. A crystal structure was obtained of 1b when bound in the ligand binding domain of GluK1. A domain opening of 13-14° was seen compared to the structure with glutamate, consistent with 1b being an antagonist. A structure-activity relationship study showed that the chemical nature of the tethering atom (C, O, or S) linking the pyrrolidine ring and the phenyl ring plays a key role in the receptor selectivity profile and that substituents on the phenyl ring are well accommodated by the GluK1 receptor.

Copper-catalyzed formal [1 + 2 + 2]-annulation of alkyne-tethered diazoacetates and pyridines: Access to polycyclic indolizines

A copper-catalyzed formal [1 + 2 + 2]-annulation of alkyne-tethered diazo compounds with pyridines, which affords polycyclic fused indolizines in synthetically useful to good yields under mild reaction conditions, has been reported. This method features the use of an inexpensive copper catalyst and readily available starting materials, broad substrate generality, and operational simplicity. Notably, a variety of natural product derivatives are compatible under the current conditions, which shows significant potential of this method for the selective decoration and modification of analogous biomolecules or pharmaceuticals.

Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach

The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.

Preparation method of carboxylic ester compound

The invention relates to a preparation method of a carboxylic ester compound, which comprises the following steps: reacting carboxylic acid with methanol in air under the catalysis of nitrite to obtain an ester compound, the preparation method disclosed by the invention has the advantages of rich raw material sources, cheap and easily available catalyst, mild reaction conditions, simplicity and convenience in operation and the like, a series of fatty carboxylic acids can be modified with high yield, and particularly, the traditional esterification method is generally not suitable for esterification of drug molecules. By utilizing the method, a series of known drug molecules can be modified, so that a shortcut is provided for discovering new drug molecules.

Green Esterification of Carboxylic Acids Promoted by tert-Butyl Nitrite

In this work, the green esterification of carboxylic acids promoted by tert-butyl nitrite has been well developed. This transformation is compatible with a broad range of substrates and exhibits excellent functional group tolerance. Various drugs and substituted amino acids are applicable to this reaction under near neutral conditions, with good to excellent yields.

New compound used as rearranged during transfection kinase inhibitor

The present invention relates to a compound, a pharmaceutical composition containing the compound, a preparation method of the compounds, and application of the same as a rearranged during transfection (RET) kinase inhibitor. The compound is a compound shown as formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvent compound, a polymorph, an isomer and a stable isotope derivativethereof. The present invention also relates to the application of the compounds to treatment or prevention of RET kinase mediated related diseases like tumors and a method of using the compounds for the treatment of the diseases.

Electrochemical Cross-Dehydrogenative Coupling between Phenols and β-Dicarbonyl Compounds: Facile Construction of Benzofurans

Preparative electrochemical synthesis is an ideal method for establishing green, sustainable processes. The major benefits of an electro-organic strategy over that of conventional chemical synthesis are the avoidance of reagent waste and mild reaction conditions. Here, an intermolecular cross-dehydrogenative coupling between phenols and β-dicarbonyl compounds has been developed to build various benzofurans under undivided electrolytic conditions. Neither transition metals nor external chemical oxidants are required to facilitate the dehydrogenation and dehydration processes. The key factor in success was the use of nBu4NBF4 as the electrolyte and hexafluoroisopropanol as the solvent, which play key roles in the cyclocondensation step. This electrolysis is scalable and can be used as a key step in drug synthesis. On the basis of several experimental results, the mechanism, particularly of the remarkable anodic oxidation and cyclization process, was illustrated.

Insights into Ruthenium(II/IV)-Catalyzed Distal C?H Oxygenation by Weak Coordination

C?H hydroxylation of aryl acetamides and alkyl phenylacetyl esters was accomplished via challenging distal weak O-coordination by versatile ruthenium(II/IV) catalysis. The ruthenium(II)-catalyzed C?H oxygenation of aryl acetamides proceeded through C?H ac

Metal-Free Tandem Rearrangement/Lactonization: Access to 3,3-Disubstituted Benzofuran-2-(3H)-ones

A novel metal-free synthesis of 3,3-disubstituted benzofuran-2-(3H)-ones through reacting α-aryl-α-diazoacetates with triarylboranes is presented. Initially, triarylboranes were successfully investigated in α-arylations of α-diazoacetates, however in the presence of a heteroatom in the ortho position, the boron enolate intermediate undergoes an intramolecular rearrangement to form a quaternary center. The intermediate cyclizes to afford valuable 3,3-disubstituted benzofuranones in good yields.